Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypertonic vs Isotonic Saline for CRS
NCT04242368Phase 3Withdrawn
- Sponsor
- Stanford University
- Start
- Jul 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 3, randomised trial of hypertonic saline in chronic rhinosinusitis (CRS) (2 arms), sponsored by Stanford University. Primary endpoints: Sino-Nasal Outcome Test-22 at 2 weeks and Nasal Obstruction Symptom Evaluation at 2 weeks. Planned start Jul 2020; status: withdrawn.
02
Drugs
hypertonic saline
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on NCT04242368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04242368.